ClinicalTrials.gg
RecruitingNCT07338682Updated Jan 21, 2026

Evaluation of the Effect of L-Arginine on the Cognitive Function in Geriatric Patients

A Phase 2 interventional study of L-Arginine and Placebo in Cognition Disorders in Old Age and Cognitive and Behavioral Impairment, sponsored by German University in Cairo. Recruiting at 1 site in Egypt. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-01-21.

Sponsored by German University in Cairo · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Registered 4 months after the study started (first participant enrolled Aug 2025, registered Jan 2026).
  • Started Aug 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Cognitive Dysfunction with a site in Egypt — 7 open to participants now, 8 under way, none of them phase 3. Cognitive Dysfunction · Egypt.

Planned enrollment
9th of 18
60 · median 60
Started
2025
with 2 others
Phase 2
Only one
of the 29
Registered
27th of 29
by date
Lead sponsor
1 of 29
German University in Cairo

Among the 29 studies in Cognitive Dysfunction with a site in Egypt, this one is the 9th largest by planned enrollment of the 18 interventional ones that give a count, is one of 3 that started in 2025, is the only one in phase 2, and was the 27th registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

7 of the 29 studies in Cognitive Dysfunction with a site in Egypt are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Cognitive Dysfunction with a site in Egypt, or all of them as a file.
02

Study summary

This study aims to evaluate the effect of L-arginine supplementation on cognitive function in geriatric patients. Eligible participants will receive either L-arginine (6 grams once daily) or placebo, and their cognitive performance will be assessed using validated cognitive assessment tools over the study period. The participants will receive the intervention for 4 weeks and followed up every 2 weeks. The primary outcome is improvement in cognitive function, while secondary outcomes include safety, tolerability, and quality of life measures. The findings may provide evidence for the potential role of L-arginine in supporting cognitive health in elderly populations.

Read the detailed description

Cognitive decline is a common problem in the geriatric population and can significantly affect independence, quality of life, and overall health outcomes. Emerging evidence suggests that L-arginine, a semi-essential amino acid and precursor for nitric oxide synthesis, may play a role in improving cerebral blood flow and neuronal function. These mechanisms could potentially contribute to better cognitive performance in elderly individuals.

This study is designed to evaluate the effect of L-arginine supplementation on cognitive function in geriatric patients. Participants who meet eligibility criteria will be randomized to receive either L-arginine supplementation or placebo. Cognitive function will be assessed at baseline and at defined intervals during the study period using validated neurocognitive assessment tools. Additional measures will include safety monitoring, tolerability, and secondary assessments such as quality of life indices.

The primary objective is to determine whether L-arginine supplementation improves cognitive function. Secondary objectives include evaluating the anti-inflammatory, antioxidant effect and safety profile of L-arginine in older adults and assessing its potential impact on daily living and overall well-being. The results of this study may provide valuable insights into the role of L-arginine in supporting cognitive health in elderly populations and inform future clinical practice.

03

Conditions studied

  • Cognition Disorders in Old Age
  • Cognitive and Behavioral Impairment

Keywords

  • L-arginine
  • Cognitive impairment
  • Geriatrics
  • Elderly
  • Cognitive Function
  • Nitric Oxide
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >60 years
  • (MoCA) test score from 10-25 (mild to moderate cognitive impairment)

Exclusion criteria

Exclusion Criteria:

  • Presence of neurodegenerative diseases (e.g.: Alzheimer's disease, Parkinson's disease, Huntington's disease, Multiple Sclerosis)
  • Patients with history of L-arginine intolerance or allergy
  • Patients with asthma
  • Patients who recently had an acute myocardial infarction
  • Patients with history of stroke within 1 yaear
  • Patients who started or discontinued medications that may affect cognitive function (e.g., CNS psychotropics, antihistamines, or acetylcholinesterase inhibitors) during the study period.
  • Patients who initiated or stopped antihypertensive medications during the study period.
  • Patients who initiated or stopped antidiabetic medications during the study period.
  • Patients who initiated or stopped antihyperlipidemic medications during the study period.
  • Patients prescribed medications for depression, anxiety, or stress that may impact cognitive function
  • Patients on nitrates, phosphodiesterase-5 inhibitors, potassium sparing diuretics
  • Refusal to provide written
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    L-Arginine

    6 grams sachets of L-arginine once daily

    Dietary Supplement: L-Arginine

  • Placebo comparator
    Placebo

    Matching placebo once daily

    Other: Placebo

Interventions

  • Dietary supplementArginineStudies of ArginineArginine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    6 grams L-arginine sachets taken orally once daily

  • OtherPlacebo

    Matching Placebo of L-arginine

06

What researchers measure

Primary outcomes

  1. Montreal Cognitive Assessment (MOCA)

    MOCA is a is a brief cognitive screening tool used to detect mild cognitive impairment (MCI) and early dementia. It assesses multiple cognitive domains including memory, attention, executive function, language, visuospatial skills, abstraction, calculation, and orientation. The score ranges from 0- 30. The higher the score the better the cognition. The normal range is from 26-30.

    Time frame: at baseline, after 2 weeks, and after 4 weeks

Secondary outcomes

  1. Depression, Anxiety, Stress Scales-21 (DASS-21)

    DASS-21 is a short self-report questionnaire used to assess depression, anxiety, and stress over the past week. It consists of 21 items, with 7 items for each subscale, rated on a 4-point Likert scale. Each subscale has a raw score range of 0-21and the higher the score the worse the outcome of symptoms of depression, anxiety, or stress.

    Time frame: at baseline, after 2 weeks, and after 4 weeks

  2. The World Health Organization Quality of Life (WHOQOL-BREF)

    WHOQOL-BREF is a brief, self-administered questionnaire that assesses an individual's perceived quality of life. It consists of 26 items covering four domains: physical health, psychological health, social relationships, and environment. Score can range from 0-100 for each domain with higher scores meaning a better quality of life.

    Time frame: at baseline, after 2 weeks, and after 4 weeks

  3. ADMA

    Asymmetric dimethylarginine

    Time frame: at baseline and after 4 weeks

  4. MDA

    Malondialdehyde

    Time frame: at baseline and after 4 weeks

  5. CRP

    C-reactive protein

    Time frame: at baseline and after 4 weeks

  6. Lipid Profile

    Time frame: at baseline and after 4 weeks

  7. Kidney Function test

    Serum Creatinine

    Time frame: at baseline and after 4 weeks

  8. Liver Function Tests

    ALT and AST

    Time frame: at baseline and after 4 weeks

07

Study locations

1 of 1 sites recruiting
  • Neurology Department, Al-Azhar University Hospitals
    Cairo, Egypt
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Jun 2026, 9 months after the start.

Of 145 non-industry phase 2 interventional studies under Cognitive Dysfunction, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 64. This study's planned 9 months is below that.

Counting every sponsor, half of 187 studies reached it within 42 months; a quarter within 22 and three quarters within 62.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2026
First posted
Jan 14, 2026
StartActual
Aug 27, 2025
Primary completionEst.
Jun 1, 2026
CompletionEst.
Jun 30, 2026
Last update
Jan 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07338682
Lead sponsor
German University in Cairo
Responsible party
Rama Elmor (Teaching Assistant/Pharmacist, German University in Cairo) — Principal investigator
First posted
Jan 14, 2026
Start date
Aug 27, 2025
Primary completion
Jun 1, 2026 (estimated)
Completion
Jun 30, 2026 (estimated)
Last update
Jan 21, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Arginine

Start the discussion